Form 4: Unicycive Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, reports acquisition of stock options.
Summary
- On August 12, 2024, Douglas Jermasek, the EVP of Corporate Strategy at Unicycive Therapeutics, acquired 81,750 stock options with an exercise price of $0.34.
- These options vest over time, with 20,438 vesting on the first anniversary of the grant date and the remaining options vesting monthly over the subsequent 36 months.
- Following this transaction, Jermasek directly owns 2,055,000 shares of Unicycive Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation packages.
Stakeholder Impact
- The transaction could have a minor impact on shareholders, as it increases the number of outstanding options.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of stock options transaction |
| 08/12/2034 | Expiration date of stock options |
| 08/14/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.